The two interleukin-1 receptors play different roles in IL-1 actions
- PMID: 8020198
- DOI: 10.1006/clin.1994.1100
The two interleukin-1 receptors play different roles in IL-1 actions
Abstract
The proinflammatory cytokine interleukin-1 binds to two cell-surface receptors. The type I receptor, an 80-kDa protein with a cytoplasmic domain of approximately 215 amino acids, mediates the biological effects of IL-1. The type II receptor, a 60-kDa protein with 29 cytoplasmic amino acids, binds IL-1 and thereby prevents it from binding to the type I receptor but does not deliver a biological signal. Thus, the type II receptor acts as a negative regulator of IL-1 actions. It can do so either as a membrane-bound molecule or subsequent to shedding from the cell surface to generate a so-called "soluble" receptor. Both the naturally produced soluble type II receptor and the recombinantly generated soluble type I receptor are effective inhibitors of IL-1 action. The soluble type I receptor has shown efficacy in some preclinical models of inflammatory diseases, as well as in an initial clinical trial in a setting of cutaneous allergy.
Similar articles
-
Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist.Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1714-8. doi: 10.1073/pnas.92.5.1714. Proc Natl Acad Sci U S A. 1995. PMID: 7878046 Free PMC article.
-
The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor.J Clin Invest. 1995 Jul;96(1):38-41. doi: 10.1172/JCI118045. J Clin Invest. 1995. PMID: 7615809 Free PMC article.
-
Shedding of the type II IL-1 decoy receptor requires a multifunctional aminopeptidase, aminopeptidase regulator of TNF receptor type 1 shedding.J Immunol. 2003 Dec 15;171(12):6814-9. doi: 10.4049/jimmunol.171.12.6814. J Immunol. 2003. PMID: 14662887
-
The interleukin-1 axis and cutaneous inflammation.J Invest Dermatol. 1995 Jul;105(1 Suppl):62S-66S. doi: 10.1111/1523-1747.ep12316087. J Invest Dermatol. 1995. PMID: 7615999 Review.
-
Interleukin-I antagonists.Ther Immunol. 1994 Apr;1(2):113-22. Ther Immunol. 1994. PMID: 7584483 Review. No abstract available.
Cited by
-
Existence of seven human IL-1R1 promoters.J Inflamm Res. 2010 Feb 1;2010(3):17-24. doi: 10.2147/JIR.S7095. J Inflamm Res. 2010. PMID: 20814588 Free PMC article.
-
Generation and Characterization of Mice Expressing a Conditional Allele of the Interleukin-1 Receptor Type 1.PLoS One. 2016 Mar 1;11(3):e0150068. doi: 10.1371/journal.pone.0150068. eCollection 2016. PLoS One. 2016. PMID: 26930558 Free PMC article.
-
Increased interleukin-1 (IL-1) and imbalance between IL-1 and IL-1 receptor antagonist during acute inflammation in experimental Shigellosis.Infect Immun. 1999 Nov;67(11):6056-66. doi: 10.1128/IAI.67.11.6056-6066.1999. Infect Immun. 1999. PMID: 10531267 Free PMC article.
-
Increased interleukin-1β levels following low dose MDMA induces tolerance against the 5-HT neurotoxicity produced by challenge MDMA.J Neuroinflammation. 2011 Nov 24;8:165. doi: 10.1186/1742-2094-8-165. J Neuroinflammation. 2011. PMID: 22114930 Free PMC article.
-
Interleukin-1 receptor type I gene-deficient mice are less susceptible to Staphylococcus epidermidis biomaterial-associated infection than are wild-type mice.Infect Immun. 2000 Dec;68(12):6924-31. doi: 10.1128/IAI.68.12.6924-6931.2000. Infect Immun. 2000. PMID: 11083815 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases